Publicaciones en las que colabora con José Luis Lanciego Pérez (15)

2023

  1. AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability

    Brain, Behavior, and Immunity, Vol. 108, pp. 255-268

  2. Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease

    Neurobiology of Disease, Vol. 188

  3. Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates

    Brain : a journal of neurology, Vol. 146, Núm. 12, pp. 5000-5014

2021

  1. An ACE2/Mas-related receptor MrgE axis in dopaminergic neuron mitochondria

    Redox Biology, Vol. 46

2018

  1. Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death

    Neurotherapeutics, Vol. 15, Núm. 4, pp. 1063-1081

  2. Gene therapy approaches in the non-human primate model of Parkinson’s disease

    Journal of Neural Transmission, Vol. 125, Núm. 3, pp. 575-589

  3. Glucocerebrosidase expression patterns in the non-human primate brain

    Brain Structure and Function, Vol. 223, Núm. 1, pp. 343-355

  4. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia

    Brain, Behavior, and Immunity, Vol. 67, pp. 139-151

2017

  1. Brain renin-angiotensin system and microglial polarization: Implications for aging and neurodegeneration

    Frontiers in Aging Neuroscience, Vol. 9, Núm. MAY

  2. Expression of angiotensinogen and receptors for angiotensin and prorenin in the rat and monkey striatal neurons and glial cells

    Brain Structure and Function, Vol. 222, Núm. 6, pp. 2559-2571

2015

  1. Critical period for dopaminergic neuroprotection by hormonal replacement in menopausal rats

    Neurobiology of Aging, Vol. 36, Núm. 2, pp. 1194-1208

  2. Dopamine D2 and angiotensin II type 1 receptors form functional heteromers in rat striatum

    Biochemical Pharmacology, Vol. 96, Núm. 2, pp. 131-142

2013

  1. Dopaminergic degeneration is enhanced by chronic brain hypoperfusion and inhibited by angiotensin receptor blockage

    Age, Vol. 35, Núm. 5, pp. 1675-1690

  2. Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease

    Neurobiology of Disease, Vol. 58, pp. 209-219

2010

  1. Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease

    Experimental Neurology, Vol. 224, Núm. 2, pp. 517-526